Celebrating 25 years Est 1999-2024
*Across 3 years $2158.56 only $1079.28
FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction...
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K x ANNUAL REPORT UNDER...
Filed Pursuant to Rule 433 Issuer Free Writing Prospectus dated March 4, 2010 Relating to Prospectus dated January 5, 2010 and Prospectus...
Filed pursuant to Rule 424(b)(5) Registration No. 333-163987 PROSPECTUS SUPPLEMENT (To Prospectus Dated January 5, 2010) ...
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT...
WALTHAM, Mass., Feb. 4 /PRNewswire-FirstCall/ -- Interleukin Genetics, Inc. (NYSE Amex: ILI) announced today that it will make a corporate...
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.